Neogen Cash Flow Statement
NASDAQ: NEOGHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD
11.85+0.14 (+1.20%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Neogen free cash flow
In fiscal 2026, Neogen generated $83.2 million of operating cash flow and spent $51.3 million on capital expenditures. That left free cash flow of $31.9 million, a free-cash-flow margin of 3.7% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Neogen cash flow statement (annual)
| Fiscal year (USD) | FY 20262026-05-31 | FY 20252025-05-31 | FY 20242024-05-31 | FY 20232023-05-31 | FY 20222022-05-31 | FY 20212021-05-31 | FY 20202020-05-31 | FY 20192019-05-31 | FY 20182018-05-31 | FY 20172017-05-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -7.90M | -1.09B | -9.40M | -22.87M | 48.31M | 60.88M | 59.48M | 60.18M | 63.22M | 43.97M |
| Net Income growth (YoY) | — | — | — | -147.34% | -20.65% | +2.37% | -1.16% | -4.81% | +43.76% | +20.35% |
| Depreciation & Amortization | 116.30M | 119.50M | 116.70M | 88.38M | 23.69M | 21.04M | 18.40M | 17.62M | 17.06M | 14.69M |
| Stock-Based Compensation | 13.40M | 17.30M | 13.80M | 10.18M | 7.15M | 6.44M | 6.47M | 5.54M | 4.91M | 5.26M |
| Change in Working Capital | 58.10M | -6.40M | -51.10M | -28.40M | -12.69M | -5.75M | -7.16M | -19.49M | -10.77M | -2.81M |
| Operating Cash Flow | 83.20M | 58.20M | 35.30M | 41.03M | 68.04M | 81.09M | 85.88M | 63.84M | 69.13M | 60.27M |
| Capital Expenditures | -51.30M | -104.60M | -111.40M | -65.76M | -24.43M | -26.71M | -24.05M | -14.66M | -20.95M | -14.58M |
| Investing Cash Flow | 70.50M | -99.20M | -29.30M | 201.04M | -97.23M | -105.56M | -88.78M | -119.15M | -83.08M | -62.14M |
| Share Repurchases | — | — | — | — | — | — | — | -3.13M | — | — |
| Debt Issued | 0 | 450.00M | 0 | 0 | — | — | — | — | — | — |
| Debt Repaid | -100.00M | -550.00M | 0 | -100.00M | 0 | 0 | — | — | — | — |
| Financing Cash Flow | -99.40M | -1.60M | 1.90M | -118.08M | 6.81M | 33.54M | 29.41M | 13.90M | 22.84M | 25.07M |
| Net Change in Cash | 56.50M | -41.60M | 7.40M | 118.77M | -31.13M | 9.33M | 24.58M | -41.39M | 5.51M | 22.31M |
| Free Cash Flow | 31.90M | -46.40M | -76.10M | -24.73M | 43.61M | 54.38M | 61.83M | 49.18M | 48.19M | 45.70M |
This table shows 10 annual periods of Neogen's cash flow statement, from FY 2026 back to FY 2017, across 13 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow NEOG's reporting calendar. What is a cash flow statement?